Table 1 Baseline patient characteristics
Exposed patients (n = 75) | Non-exposed patients (n = 150) | ||
|---|---|---|---|
Gender (female) | 18 (24%) | 38 (25%) | * |
Mean age (years) | 44 | 46 | * |
Weight (kg) | 70 | 72 | * |
Mechanism of transmission | * | ||
Homosexual | 18 (25%) | 37 (25%) | * |
IVDU | 29 (39%) | 52 (35%) | * |
Heterosexual | 19 (25%) | 48 (32%) | * |
Unknown | 7 (9%) | 12 (8%) | * |
Concomitant pathologies | * | ||
AIDS | 18 (24%) | 46 (30%) | * |
HCV | 31 (40%) | 56 (39%) | * |
Psychiatric history | 17 (23%) | 27 (18%) | * |
Methadone consumption | 5 (6%) | 22 (14%) | * |
Use of psychopharmaceuticals | 14 (19%) | 19 (13%) | * |
FDCs | * | ||
AtriplaTM | 36 (48%) | 72 (48%) | * |
TruvadaTM | 24 (32%) | 48 (32%) | * |
KivexaTM | 7 (9%) | 16 (11%) | * |
CombivirTM | 6 (8%) | 14 (9%) | * |
TrizivirTM | 2 (3%) | 0 (0%) | * |
NNRTI | 15 (20%) | 28 (19%) | * |
PI | 22 (29%) | 54 (36%) | * |
Integrase | 0 (0%) | 3 (2%) | * |
Exposure time to FDCs (months) | 27 (range: 1–121) | 24 (range: 3–98) | * |
Exposure time to efavirenz (months) | 50 (range: 129–1) | 61 (range: 126–3) | * |
Viral load > 50 copies/mL at visit −1 | 12 of 74 (16.2%) | 8 of 149 (5.4%) | (OR: 3.4; 95%CI: 1.3-8.8; p = 0.02) |
Viral load > 50 copies/mL at baseline visit | 10 of 74 (13.5%) | 10 of 146 (6.8%) | * |
CD4 at first visit (cells/μL) | 573 (range: 41–1527) | 542 (range: 92–1481) | * |